Compare NTIC & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | QTTB |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 97.5M |
| IPO Year | 1996 | 2018 |
| Metric | NTIC | QTTB |
|---|---|---|
| Price | $8.10 | $11.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 11.7K | ★ 1.4M |
| Earning Date | 04-09-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $84,234,474.00 | $53,737,000.00 |
| Revenue This Year | $12.49 | N/A |
| Revenue Next Year | $7.64 | N/A |
| P/E Ratio | $402.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.14 | $1.40 |
| 52 Week High | $10.03 | $14.85 |
| Indicator | NTIC | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 57.73 |
| Support Level | $7.86 | $2.93 |
| Resistance Level | $8.25 | $14.85 |
| Average True Range (ATR) | 0.13 | 1.56 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 60.00 | 27.43 |
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).